Abstract
Spinocerebellar ataxia type 3/Machado–Joseph disease (SCA3) is the most common autosomal dominant ataxia. In view of the development of targeted therapies for SCA3, precise knowledge of stage-dependent fluid and MRI biomarker changes is needed.
We analyzed cross-sectional data of 292 SCA3 mutation carriers including 57 pre-ataxic individuals, and 108 healthy controls from the European Spinocerebellar ataxia type 3/Machado-Joseph Disease Initiative (ESMI) cohort. Blood concentrations of mutant ATXN3 and neurofilament light (NfL) were determined, and volumes of pons, cerebellar white matter (CWM) and cerebellar grey matter (CGM) were measured on MRI.
Mutant ATXN3 concentrations were high before and after ataxia onset, while NfL continuously increased and deviated from normal 11.9 years before onset. Pons and CWM volumes decreased, but the deviation from normal was only 2.0 years (pons) and 0.3 years (CWM) before ataxia onset. We propose a staging model of SCA3 that includes an initial asymptomatic carrier stage followed by the biomarker stage defined by absence of ataxia, but a significant rise of NfL. The biomarker stage leads into the ataxia stage, defined by manifest ataxia.
The present analysis provides a robust framework for further studies aiming at elaboration and differentiation of the staging model of SCA3.
Competing Interest Statement
GO consults for IXICO Technologies Limited, which provides neuroimaging services and digital biomarker analytics to biopharmaceutical firms conducting clinical trials for SCAs, and receives research support from Biogen, which develops therapeutics for SCAs. MS has received consultancy honoraria from Janssen, Ionis, Orphazyme, Servier, Reata, GenOrph, and AviadoBio, all unrelated to the present manuscript. LS received consultancy honoraria from Vico Therapeutics and Novartis unrelated to the present manuscript. LPA research group has private funding from PTC Therapeutics, Uniqure, Wave life Sciences, Servier, Blade Therapeutics and Hoffmann-La Roche AG outside the submitted work.
Funding Statement
This publication is an outcome of ESMI, an EU Joint Programme - Neurodegenerative Disease Research (JPND) project (see www.jpnd.eu). The project is supported through the following funding organisations under the aegis of JPND: Germany, Federal Ministry of Education and Research (BMBF; funding codes 01ED1602A/B); Netherlands, The Netherlands Organisation for Health Research and Development; Portugal, Fundacao para a Ciencia e Tecnologia (funding code JPCOFUND/0002/2015); United Kingdom, Medical Research Council (MR/N028767/1). This project has received funding from the European Unions Horizon 2020 research and innovation programme under grant agreement No 643417. On the Azores ESMI Network is currently supported by the Regional Government (Fundo Regional para a Ciencia e a Tecnologia FRCT), under the PRO-SCIENTIA program. At the US sites this work was in part supported by the National Ataxia Foundation and the National Institute of Neurological Disorders and Stroke (NINDS) grant R01NS080816. The Center for Magnetic Resonance Research is supported by the National Institute of Biomedical Imaging and Bioengineering (NIBIB) grant P41 EB027061, the Institutional Center Cores for Advanced Neuroimaging award P30 NS076408 and S10 OD017974 grant. JF received funding as a fellow of the Hertie Network of Excellence in Clinical Neuroscience. MR is supported by FCT (CEECIND/03018/2018). BvdW receives funding from ZonMw, NWO, Gossweiler Foundation, Brugling Fonds, Radboudumc, Hersenstichting. DT received research grants from the Deutsche Forschungsgemeinschaft (DFG), European Union (EU), the Bernd Fink Foundation and the Once Upon a Time Foundation. CO receives funding from NINDS #U01 NS104326; National Ataxia Foundation; Robert and Nancy Hall Brain Research Fund. JS was supported in part by the National Ataxia Foundation and the MINDlink Foundation. JJ received grant support from NIH and Friedrichs Ataxia Research Alliance (FARA). AT received research grants from the University Medicine Essen Clinician Scientist Academy (UMEA)/Deutsche Forschungsgemeinschaft (DFG, grant number: FU356/12-1), the Mercator Research Foundation, the German Heredoataxia Society (DHAG) and Freunde und Foerderer der Neurologie der Universitaetsmedizin Essen. At the Portuguese sites, MMS and LPA received funding from European Regional Development Fund (ERDF), through the Centro 2020 Regional Operational Program; through the COMPETE 2020, Operational Programme for Competitiveness and Internationalisation, and Portuguese national funds via FCT Fundacao para a Ciencia e a Tecnologia, under the projects: CENTRO-01-0145-FEDER-181240, 2022.06118.PTDC, UIDB/04539/2020, UIDP/04539/2020, LA/P/0058/2020, ViraVector (CENTRO-01-0145-FEDER-022095), ReSet - IDT-COP (CENTRO-01-0247-FEDER-070162), Fighting Sars-CoV-2 (CENTRO-01-01D2-FEDER-000002), BDforMJD (CENTRO-01-0145-FEDER-181240), ModelPolyQ2.0 (CENTRO-01-0145-FEDER-181258), MJDEDIT (CENTRO-01-0145-FEDER-181266); ARDAT under the IMI2 JU Grant agreement No 945473 supported by the European Unions H2020 programme and EFPIA; by the American Portuguese Biomedical Research Fund (APBRF) and the Richard Chin and Lily Lock Machado-Joseph Disease Research Fund. PS (SFRH/BD/148451/2019) and MMP (2022.11089.BD) are supported FCT. PS was supported by Portuguese Foundation for Science and Technology (FCT) under the fellowship grant SFRH/BD/148451/2019. CW was supported by the Clinician Scientist Program of the Medical Faculty Tubingen (480-0-0).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The following ethics committees were asked to evaluate the study: Ethics committee/IRB of the University Hospital Bonn, Bonn, Germany, gave ethical approval of this work; the ethics committee/IRB of the University Hospital Essen as well as the RWTH Aachen gave ethical approval of this work and referred to the approval in Bonn. Ethics committee/IRB of the University of Tuebingen, Germany, gave ethical approval of this work. Ethics committee/IRB of the University of Coimbra, Coimbra, Portugal, gave ethical approval of this work. Ethics committee/IRB of the Universidade dos Acores, Ponta Delgada, Portugal, gave ethical approval of this work. Ethics committee/IRB of the University College London, UK, gave ethical approval of this work. Ethics committee/IRB of the Radboud university medical center, Nijmegen, The Netherlands, gave ethical approval of this work. Ethics committee/IRB of the University of Minnesota, Minneapolis, MN, gave ethical approval of this work. Ethics committee/IRB of the University Hospital Marques de Valdecilla-IDIVAL, Santander, Spain, gave ethical approval of this work. Ethics committee/IRB of the Johns Hopkins University School of Medicine, Baltimore, Maryland USA, gave ethical approval of this work. Ethics committee/IRB of the University Hospital Heidelberg, Heidelberg, Germany, gave ethical approval of this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Due to the sensitive nature of the data on rare diseases, access to the data can only be granted upon reasonable request, subject to the General Data Protection Regulation (GDPR) and any other relevant data protection laws. Please contact Jennifer Faber and Thomas Klockgether (jennifer.faber{at}dzne.de, thomas.klockgether{at}ukbonn.de) to submit a data access request.
